These include underlying lung diseases (interstitial lung diseases, chronic obstructive pulmonary disease), performance status, prior thoracic radiotherapy, and the treatment combination of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors with ICIs [42]. Here, EGFR is linked to chronic obstructive pulmonary disease.